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malignant disease is greater than 80% and 
90%, respectively [10–16]. However, to our 
knowledge, the accuracy of CT-guided core 
biopsy of GGO lesions has not been reported 
in detail. Thus, the purpose of this study was 
to evaluate the diagnostic accuracy of CT-
guided core biopsy of GGO lesions.
Materials and Methods
Our institutional review board approved this 
study and waived informed patient consent.
Study Population and Biopsy Indication
We retrospectively reviewed the medical and 
imaging records of all patients who underwent 
CT-guided needle biopsy of pulmonary nodules 
at our institution between June 1, 2003, and April 
30, 2006. Two chest radiologists who had 8 and 
12 years of experience in chest CT interpretation 
identified GGO lesions on CT by consensus. 
Images were displayed with a lung window setting 
(center, –600 H; width, 1,500 H). The GGO 
components were semiquantitatively classified 
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ith recent advances in CT 
screening for lung cancer, an in-
crease in the detection of 
ground-glass opacity (GGO) le-
sions has been noted [1–3]. GGO is a nonspe-
cific finding that may be caused by various 
disorders, including inflammatory diseases, 
focal fibrosis, atypical adenomatous hyperpla-
sia, bronchoalveolar carcinoma (BAC), and 
adenocarcinoma [4–6]. The clinical signifi-
cance of localized GGO is its high incidence 
of malignancy compared with solid nodules 
[7, 8]. The approach to the diagnosis of local-
ized GGO is often difficult. Currently, most 
cases of localized GGO detected at initial CT 
are reevaluated with follow-up CT after a 2- 
or 3-month interval. Whether lung biopsy 
should be considered for persistent GGO re-
mains controversial [9].
Percutaneous transthoracic needle biopsy 
is a well-established method in the histo-
logic diagnosis of pulmonary nodules, and 
the accuracy of diagnosis of benign and 
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OBJECTIVE. The purpose of our study was to evaluate the accuracy of CT-guided per-
cutaneous core biopsy of ground-glass opacity (GGO) pulmonary lesions.
MATERIALS AND METHODS. The study included 50 patients (24 men, 26 women; 
age range, 43–78 years) who had a GGO pulmonary lesion and underwent CT-guided core 
biopsy. Diagnostic accuracy was compared between two groups according to lesion size (< 2 
cm vs ≥ 2 cm) and GGO component (> 90% vs 50–90%). Each case was reviewed for compli-
cations, including pneumothorax, thoracostomy tube insertion, and hemoptysis.
RESULTS. Malignancy was finally diagnosed in 33 patients, including three who under-
went repeated biopsies, with 33 true-positive and three false-negative findings for an overall 
sensitivity of 92% (33/36). A benign lesion was finally diagnosed in 10 patients with one 
false-positive result, for a specificity of 90%. Two benign lesions without confirmative di-
agnosis because of loss of follow-up and five nondiagnostic samples were excluded from 
the calculations of sensitivity, specificity, and diagnostic accuracy. The overall diagnostic 
accuracy was 91%, with a positive predictive value of 97% and a negative predictive value 
of 75%. Sensitivity and accuracy were not significantly different between the two groups of 
lesion size and GGO components (p = 0.0491). Ten (18%) patients had pneumothorax, with 
one (2%) requiring placement of a thoracostomy tube. Mild hemoptysis occurred in seven 
(13%) patients.
CONCLUSION. CT-guided core biopsy of GGO lesions can yield high diagnostic ac-
curacy and acceptable complication rates approaching those of solid lesions.
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according to the area they occupied in the whole 
lesion. GGO was defined as an area of increased 
attenuation without obscuration of the underlying 
vessels and bronchi [17]. The percentage of DGGO 
was calculated as follows: ([DGGO – D] / DGGO 
) × 100, where DGGO is the greatest diameter of 
the lesion, including the GGO area, and D is the 
greatest diameter of the lesion without GGO. GGO 
lesions were classified into two groups according 
to the lesion diameter (< 2 cm vs ≥ 2 cm) and the 
percentage of the GGO component (> 90% vs 50–
90%). Lesions with a GGO component less than 
50% were excluded from this study because these 
lesions are mainly solid in nature.
The study included 50 patients (24 men, 26 
women; age range, 43–78 years; mean age, 61 
years); 29 patients found during lung cancer 
screening studies and 21 patients found during 
studies for clinical reasons. The mean lesion 
diameter was 1.9 ± 0.9 (SD) cm (range, 0.7–4.5 
cm). Three lesions were rebiopsied because of 
a radiologic suspicion of malignancy. A repeat 
biopsy was considered a new procedure for 
purposes of calculating diagnostic accuracy.
In our institution, we perform follow-up CT for 
initially detected GGO lesions after a 2- or 3-month 
interval. The biopsy method for the persistent 
GGO lesion (i.e., CT-guided vs surgical biopsy) 
is determined on an individual basis considering 
radiologic and clinical features and the views of the 
patient. All biopsies were performed at the request 
of pulmonary physicians or surgeons for persistent 
and localized GGO lesions after an observation 
period of several months (mean, 2.4 months).
Biopsy Procedures and Histologic Diagnosis
The biopsies were performed by experienced 
chest radiologists who had 5 and 9 years of 
experience performing thoracic biopsy. Written 
informed consent was obtained from each patient 
before each biopsy. All biopsies were performed 
under CT guidance using a 16-MDCT scanner 
(MX 8000 IDT, Philips Medical Systems). At the 
time of biopsy, selected images were obtained in 
the area of interest with 3-mm-thick contiguous 
transverse CT sections. Biopsies were planned 
to avoid visible bullae and to cross the fewest 
pleural surfaces. The procedure was performed 
with the patient in a prone, supine, or lateral 
decubitus position, depending on the location of 
the lesion. Local anesthesia was administered by 
means of a subcutaneous injection of 1% lidocaine 
(Xylocaine, AstraZeneca). A core biopsy specimen 
was obtained with a detachable 18- or 20-gauge 
automated cutting needle (Acecut, TSK Laboratory). 
Using intermittent CT scans to evaluate the needle 
trajectory, the needle was inserted through the 
pleura and advanced to a position close to a target 
lesion. After the position of the needle tip position 
was confirmed on CT scans, the automated needle 
biopsy system was fired. Decisions to perform 
additional needle passes were based on whether, on 
visual inspection, the specimen was deemed safe 
and feasible by the radiologists. Core specimens 
were immersed in 10% formalin for pathologic 
examination and diagnosis by several pathologists. 
The histologic categories used for diagnosis of 
adenocarcinoma included BAC, adenocarcinoma 
with BAC features, and adenocarcinoma that was 
not bronchoalveolar. Cases classified as BAC fit 
the 2004 World Health Organization description 
of BAC; namely, an adenocarcinoma with a pure 
bronchoalveolar growth pattern and no evidence 
of stromal, vascular, or pleural invasion [18].
Postprocedure Imaging and Care
After biopsy, CT images were obtained to 
verify the appearance of the lung and to check for 
immediate pneumothorax and hemorrhage. The 
patients were monitored in a ward and positioned 
with the puncture side down. A posteroanterior 
expiratory chest radiograph with the patient erect 
was obtained 3 hours after biopsy. If a small 
asymptomatic pneumothorax developed, the 
patient was treated conservatively with monitoring 
of vital signs, administration of supplemental 
oxygen, and follow-up chest radiography 1 hour 
later to evaluate the stability of the pneumothorax. 
Patients with pneumothorax that was enlarging 
or accompanied by symptoms of shortness of 
breath, pain, or low oxygen saturation received 
chest tubes. Chest tubes were placed by the chest 
radiologist who performed the biopsy.
Data Collection and Statistical Analysis
The medical and imaging records of all 
patients were reviewed by two chest radiologists, 
and data were collected concerning size and GGO 
component of the lesions, length of the needle 
path (i.e., length of the aerated lung traversed by 
the needle from the surface of the pleura to the 
proximal margin of the target lesion), number 
of pleural punctures, results of histopathologic 
and microbiologic examinations of the biopsy 
specimen, and complications. Agreement between 
results of the core needle and surgical biopsies 
was evaluated.
The sensitivity, specificity, positive and negative 
predictive values, and diagnostic accuracy were 
also calculated for patients, with subsequent 
follow-up data on the basis of clinical and imaging 
follow-up and review of medical records for at least 
12 months after biopsy. The pathologic results of 
needle biopsy and surgery were reviewed and 
divided into diagnostic categories that included 
malignant or premalignant (atypical adenomatous 
hyperplasia), benign, and nondiagnostic. A 
designation of a malignant or premalignant lesion 
was considered a positive result.
A positive biopsy result was considered to be 
true-positive when there was surgical confirmation 
or when the results of biopsy of another site 
revealed malignancy with the same histologic 
characteristics. A positive biopsy result was 
considered to be false-positive when there was 
no evidence of malignancy at surgical resection 
without preoperative chemotherapy or when there 
was nodule regression at follow-up CT in the 
absence of therapy. Designation of a benign lesion 
was considered a negative result. A negative biopsy 
result was considered to be true-negative when there 
was a definitive diagnosis of a benign entity, such 
as pneumonia or tuberculosis, or when the lesion 
subsequently disappeared or decreased in size at 
follow-up CT. A negative result was considered to 
be false-negative when there was surgical resection 
with a diagnosis of malignancy.
We compared the results between the two groups 
according to lesion size (< 2 cm vs ≥ 2 cm) and 
GGO component (> 90% vs 50–90%): sensitivity, 
specificity, diagnostic accuracy, incidence of 
adequate samples for histopathologic analysis, and 
lesion depth. Diagnostic accuracy was calculated 
by comparing core needle biopsy results with the 
final diagnosis based on postsurgical pathologic 
examinations (n = 34) or follow-up imaging 
(n = 9). Procedures in which the tissue specimens 
were deemed nondiagnostic (n = 5) and in which 
a definite diagnosis of benignancy or malignancy 
could not be established (n = 2) because of loss 
of follow-up were excluded from the calculation 
of sensitivity, specificity, and diagnostic accuracy. 
Fisher’s exact test was used to assess the statistical 
significance of the difference in diagnostic accuracy 
between the two biopsy groups according to the 
lesion size and the GGO component, respectively. 
An unpaired Student’s t test was used to assess the 
statistical significance of the difference between 
the two groups according to the GGO component. 
A value for p of less than 0.05 was considered to 
indicate statistical significance.
Results
Malignancy or premalignant lesions iden-
tified at CT-guided core biopsy underwent 
surgical resection for histologic confirma-
tion and treatment. Eighteen patients with 
adenocarcinoma with a BAC feature on core 
biopsy were confirmed as having the same 
histology at surgical resection. In 13 patients 
diagnosed as having BAC at core biopsy, sev-
en patients were confirmed to have adenocar-
cinoma with a BAC feature, and six patients 
were confirmed to have BAC after surgical 
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resection (Fig. 1). One patient diagnosed as 
having atypical adenomatous hyperplasia at 
core biopsy was confirmed to have BAC af-
ter surgical resection. One patient had find-
ings compatible with histologic findings in a 
preexisting primary malignancy (goblet cell 
carcinoid tumor of the appendix).
A benign finding was identified in 12 pa-
tients; of these, two samples were not con-
firmed because of loss of findings. Two pa-
tients were diagnosed with pneumonia on 
chest radiography or CT at 12- and 18-month 
follow-up periods, respectively. Two patients 
were diagnosed with interstitial fibrosis and 
two with eosinophilic pneumonia. One pa-
tient who showed interstitial pneumonia at 
core biopsy was confirmed to have interstitial 
pneumonia at surgical biopsy. One patient 
who was diagnosed with atypical adenoma-
tous hyperplasia at core biopsy was found 
to have chronic interstitial fibrosis at surgi-
cal resection. In the remaining two patients, 
one was confirmed to have tuberculosis and 
the other was confirmed to have organiz-
ing pneumonia at core biopsy. These lesions 
showed regression at follow-up imaging.
Malignancy or a premalignant lesion was 
finally diagnosed in 33 patients, including 
three repeated biopsies, with 33 true-positive 
and three false-negative findings and an over-
all sensitivity of 92% (33/36). A benign lesion 
was finally diagnosed in 10 patients with one 
false-positive result (one case of atypical ad-
enomatous hyperplasia on the needle biopsy 
specimen), generating a specificity of 90%. 
The overall diagnostic accuracy was 91%, 
with a positive predictive value of 97% and 
a negative predictive value of 75%. Five of 
53 biopsy specimens did not allow diagnosis 
(i.e., nondiagnostic samples); thus, the per-
centage of diagnostic samples at core biopsy 
was 91%. Repeated biopsies for the same lung 
lesion were performed on three patients. Ini-
tial biopsy results were suggestive of benign 
or atypical findings, and second biopsy results 
were adenocarcinoma (n = 1) and BAC (n = 
2), respectively. These three patients were 
confirmed as adenocarcinoma with BAC fea-
tures (n = 2) and BAC (n = 1), respectively, at 
surgical resection. The final diagnoses of 50 
GGO lesions are summarized in Table 1.
Results for lesions ≥ 2 cm in diameter (n = 
23; sensitivity, 94% [17/18]; accuracy, 96% 
[22/23]) were not statistically different from 
those for lesions < 2 cm in diameter (n = 
23; sensitivity, 94% [17/18]; accuracy, 91% 
[20/22]) (p = 1.0). All five nondiagnostic 
samples were obtained in patients with lesions 
< 2 cm in diameter (p = 0.0491). The lesion 
depths were not statistically different between 
the two groups (p = 0.4082) (Table 2). Results 
for lesions with GGO > 90% (n = 21; sensitiv-
ity, 93% [13/14]; accuracy, 91% [19/21]) were 
not statistically different from those for le-
sions with a GGO of 50–90% (n = 25; sen-
sitivity, 91% [20/22]; accuracy, 92% [23/25]) 
(p = 1.0). Nondiagnostic samples were ob-
tained in one of 25 lesions with 50–90% 
GGO components and four of 21 lesions with 
> 90% GGO components (p = 0.1628). The 
mean diameter of the lesions with a 50–90% 
GGO area (mean, 2.2 ± 0.9 cm) was larger 
than that of the lesions with a > 90% GGO 
area (mean, 1.6 ± 0.7 cm) (p = 0.0072). Le-
sion depths were not statistically different 
between the two groups (p = 0.3343) (Table 
3). Most biopsy procedures were completed 
with one pleural puncture, except for two cas-
es with an additional puncture.
Postbiopsy pneumothorax was seen in 10 
(18%) patients on chest radiography 3 hours 
after biopsy, and one patient required thora-
costomy tube placement. Alveolar hemor-
rhage along the needle path or around the 
target lesion developed in 13 patients (23%) 
with no major clinical sequelae. Mild he-
moptysis occurred in seven patients (13%). 
No patient with pulmonary hemorrhage or 
hemoptysis required treatment.
The overall concordance rate between 
core and surgical biopsies in malignant and 
premalignant lesions was 73% (Table 4). In 
seven cases the core biopsy specimen did not 
identify the area of invasion, and the lesions 
were subsequently diagnosed as adenocarci-





Fig. 1—CT-guided core biopsy in 60-year-old woman with pure ground-glass opacity (GGO) lesion in right 
upper lobe.
A, High-resolution CT scan shows 3-cm pure GGO lesion in right upper lobe.
B, CT scan obtained during biopsy shows biopsy needle targeting GGO lesion.
C, Photomicrograph shows gross core biopsy specimen. (H and E, ×10)
D, Photomicrograph reveals that alveolar walls are lined by cellular proliferation of atypical pneumocytes 
with hobnail morphology. No evidence of stromal invasion is seen. Histologic diagnosis of core biopsy was 
bronchoalveolar carcinoma. Final diagnosis after surgical resection was bronchoalveolar carcinoma, Noguchi 
type A. (H and E, ×200)
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tion. Two patients with atypical adenomatous 
hyperplasia at core biopsy were confirmed to 
have BAC and chronic inflammation, respec-
tively, after surgical resection.
Discussion
With recent advances in CT screening, the 
detection of small peripheral lung cancer has 
been increasing. Most CT-detected lung can-
cers are adenocarcinomas, which frequently 
show GGO on CT [1–3]. There has been much 
interest in the CT features and pathology of 
GGO, and much has been learned from the 
correlation of CT images with histology [7, 
19–22]. The diagnosis and treatment of GGO 
have become important issues; however, there 
is no generally accepted guideline for the man-
agement of GGO. Most patients with GGO 
detected on initial CT underwent follow-up 
CT after 2- to 3-month intervals [23]. Patients 
with persistent GGOs usually undergo inter-
ventional procedures, such as CT-guided bi-
opsy or video-assisted thoracoscopic surgery 
(VATS), for the establishment of a histologic 
diagnosis, which depends on the expertise and 
equipment of each institute [23–25].
Percutaneous transthoracic needle biopsy 
with CT guidance has been shown to be a 
relatively safe and accurate method for estab-
lishing the diagnosis of pulmonary lesions. 
Its diagnostic accuracy has been reported 
as greater than 80% for benign disease and 
greater than 90% for malignant disease 
[10–16]. The overall diagnostic accuracy, 
sensitivity, and specificity of CT-guided 
core biopsy in this study are similar to those 
obtained in previous studies [10–16, 26], 
although the previous results were obtained 
from solid nodules. For GGO lesions, to our 
knowledge, there is only one previous study 
in which the diagnostic accuracy of CT-
guided needle aspiration was evaluated [25]. 
Those authors compared the diagnostic accu-
racy of CT-guided needle aspiration between 
the GGO and solid lesions smaller than 2 cm, 
and suggested that the diagnostic accuracy of 
CT-guided needle aspiration for GGO lesions 
was less than that for solid lesions. The lower 
accuracy was probably due to the low cellu-
larity of GGO lesions, which may frequently 
result in an inadequate aspiration of air or 
blood. In addition, the cytologic diagnosis of 
BAC is difficult with aspiration biopsy speci-
mens compared with those of a solid tumor. 
The cytologic features of BAC in aspiration 
biopsy specimens may merge with those of 
reactive type 2 pneumocyte hyperplasia and 
with those of borderline lesions such as scle-
rosing hemangioma [27, 28].
Previous studies have reported various fac-
tors affecting the diagnostic accuracy of CT-
guided needle aspiration and biopsy of lung 
nodules [11, 12, 16, 28–34]. Although the size 
and type of needle used in needle aspiration 
and biopsy were unlikely to influence the di-
agnostic sensitivity for lung cancer [29, 35–38], 
these factors has been reported to affect the 
diagnostic sensitivity for benign diseases and 
lymphoma [37, 39]. We performed CT-guided 
core biopsy using an automated gun that can 
obtain core specimens to overcome these limi-
tations of the needle aspiration of GGO lesions. 
The higher accuracy in our study might be due 
to the use of core biopsy, which can obtain ad-
equate core specimens rather than the scanty 
cellular aspirates from GGO lesions.
Although our results showed a concor-
dance rate of 73% in malignant and prema-
lignant lesions, there were several cases of 
discrepancy between the needle and surgical 
biopsy results; for seven BACs at core biopsy, 
the area of invasion was not identified. Given 
the requirement for BAC to show pure lepidic 
growth without invasion and the knowledge 
that most lung adenocarcinomas with a BAC 
component also have an area of invasion, it is 
impossible to make an unequivocal diagnosis 
of BAC in small biopsy specimens [21, 40]. 
Thus, the correlation with thin-section CT 
images is warranted when the results of core 
biopsy suggest BAC, and the entire lesion 
should be removed to exclude invasion before 
a final diagnosis of BAC can be made.
When comparing diagnostic accuracy ac-
cording to lesion size, no statistically signifi-
cant difference was seen. However, all five 
nondiagnostic samples were obtained in le-
sions smaller than 2 cm. This result is com-
parable to the findings of other reports in the 
literature [14, 30–33]. In a study of diagnos-
tic accuracy of CT-guided aspiration biopsy 
classifying lesions into two groups by size, 
Tsukada et al. [16] reported that the accuracy 
was 76.4% for lesions ≤ 2 cm in diameter and 
89.4% for those > 2 cm in diameter, which 
shows the difficulty of obtaining an accurate 
diagnosis with smaller lesions.
To our knowledge, there has been no report 
regarding the diagnostic accuracy of core bi-
opsy of GGO lesions according to the GGO 
components. Contrary to the general expecta-
tion that it is more difficult to obtain adequate 
samples as the GGO components increase, di-
TABLE 1: Final Diagnoses of  
50 Lesions with Ground-
Glass Opacity


















Chronic active inflammation 1






Note—BAC = bronchoalveolar carcinoma.
aIncludes one repeated biopsy.
bIncludes two repeated biopsies.
cPatients lost to follow-up.
TABLE 2: Diagnostic Yield and Accuracy Based on Lesion Size
Variable
Greatest Diameter
p≥ 2 cm < 2 cm
Sensitivity (%)a 94 (17/18) 94 (17/18) 1.0
Accuracy (%)a 96 (22/23) 91 (21/23) 1.0
Lesion depth (mm) 18 21 0.4082
No. of nondiagnostic samples   0 5 0.0491
aNumbers of patients used to calculate percentages are in parentheses. Diagnostic yield and accuracy 
were calculated on basis of 46 biopsy results, excluding five nondiagnostic samples and two samples 
without confirmative diagnosis due to loss of follow-up.
238 AJR:190, January 2008
Kim et al.
agnostic accuracy was not statistically differ-
ent between the two groups. This result might 
also be related to the use of a cutting needle 
rather than an aspiration needle. However, 
nondiagnostic samples were more frequent 
in lesions with > 90% GGO components (n = 
4) compared with lesions with 50–90% GGO 
(n = 1). Further study is necessary to evalu-
ate the diagnostic accuracy of core biopsy 
according to GGO components of the lesions.
Our pneumothorax rate (18%) was similar 
to or lower than the reported rates in the lit-
erature (22–45%) [30, 33, 41, 42]. Our lower 
incidence of pneumothorax was likely the re-
sult of two main factors. First, we minimized 
the number of pleural punctures; most proce-
dures were completed with a single puncture. 
The pneumothorax rate in patients with single 
punctures is significantly less than in patients 
with three punctures [33]. Second, there was 
no intrabiopsy delay for cytopathology evalu-
ation [29]. The prevalence rates of pulmonary 
hemorrhage and hemoptysis were also in the 
range of reported complication rates [14–16, 
26, 28–32]. These complications did not ap-
pear to be clinically significant because none 
of the patients required treatment.
Currently, no guideline exists for the man-
agement of GGO lesions. In our institute, le-
sions of < 1 cm in diameter are followed up 
with thin-section CT 2–3 months later, and 
those of ≥ 1 cm in diameter are examined with 
CT-guided needle biopsy or VATS. Lesions 
that increase beyond 1 cm or with a newly de-
veloped solid component at follow-up CT also 
undergo CT-guided needle biopsy or VATS. 
It is generally acknowledged that pulmonary 
lesions with a high probability of malignancy 
that are resectable should proceed directly 
to surgery because neither a positive nor a 
negative needle biopsy result is likely to alter 
management [43]. However, in terms of daily 
clinical routine, patients may be unwilling to 
contemplate thoracotomy without preoperative 
confirmation of malignancy [44–46]. In fact, 
in our institute many patients with persistent 
GGO are reluctant to undergo surgical resec-
tion without preoperative histologic confir-
mation. Most GGO lesions are detected in an 
asymptomatic screening population, and they 
typically show no significant interval change 
on follow-up imaging. A good chance of a diag-
nosis of lung cancer with GGO is another pos-
sible explanation for this reluctance. Although 
VATS biopsy can provide larger tissue speci-
mens and improve accuracy, the morbidity and 
length of stay are greater than those with core 
biopsy; thus, the decision as to whether to per-
form core biopsy or surgical resection should 
be determined on an individual basis, consider-
ing not only the clinical and radiologic features 
but also the views of the patient.
Our study has several limitations. First, the 
follow-up duration was shorter than that of other 
studies. Pulmonary nodules are considered be-
nign if they show no growth for 2 years; how-
ever, GGO lesions such as atypical adenomatous 
hyperplasia or BAC may persist without an in-
terval change long after a 2-year follow-up pe-
riod [47, 48]. There is a possibility of a missed 
lung cancer in patients without confirmative 
diagnosis; thus, we arranged for these patients 
to be followed up with serial CT. Second, to in-
terpret the performance of any diagnostic pro-
cedure, the pretest probability of malignancy 
should be known. Our study population includ-
ed patients with persistent GGO and a high in-
cidence of malignancy; thus, the overall preva-
lence of malignancy might be higher than that 
of solitary pulmonary nodules encountered in a 
clinical setting [49]. Third, in patients who are 
candidates for surgery, the role of preoperative 
imaging-guided biopsy is unclear. However, this 
does not change the focus of this study, which 
was to determine the diagnostic accuracy of CT-
guided core biopsy for GGO lesions.
In conclusion, the results of this study sug-
gest that CT-guided core biopsy of pulmonary 
GGO lesions can yield high diagnostic accura-
cy and acceptable complication rates approach-
ing those of solid lesions. It can be a safe and 
accurate diagnostic alternative to surgical bi-
opsy, especially when patients are unwilling to 
undergo surgical biopsy or take surgical risks.
References
 Kaneko M. Peripheral lung cancer: screening and 1. 
detection with low-dose spiral CT versus radiog-
raphy. Radiology 1996; 201:798–802
 Sone S, Takashima S, Li F, et al. Mass screening 2. 
for lung cancer with mobile spiral computed to-
mography scanner. Lancet 1998; 351:1242–1245
 Henschke CI, McCauley DI, Yankelevitz DF, et al. 3. 
Early Lung Cancer Action Project: overall design 
and findings from baseline screening. Lancet 1999; 
354:99–105




Sensitivity (%)a 91 (20/22) 93 (13/14) 1.0
Accuracy (%)a 92 (23/25) 91 (19/21) 1.0
Lesion diameter (mm) 22 16 0.0072
Lesion depth (mm) 21 18 0.3343
No. of nondiagnostic 
samples
  1   4 0.1628
aNumbers of patients used to calculate percentages are in parentheses. Diagnostic yield and accuracy 
are calculated based on 46 biopsy results excluding five nondiagnostic samples and two samples without 
confirmative diagnosis due to loss of follow-up.
TABLE 4: Comparison of Histologic Diagnoses from Core Biopsy and Surgery 
in Malignant and Premalignant Lesions
Core Biopsy Surgical Biopsy No. of Lesions
Concordant
Adenocarcinoma with BAC 
feature










AAH Chronic inflammation 1
Total 9
Total overall 33
Note—BAC = bronchoalveolar carcinoma, AAH = atypical adenomatous hyperplasia.
AJR:190, January 2008 239
CT-Guided Biopsy of Pulmonary Lesions
Kushihashi T. Bronchioloalveolar adenoma of the 4. 
lung: CT–pathologic correlation. Radiology 1994; 
193:789–793
 Collins J, Stern EJ. Ground-glass opacity at CT: 5. 
the ABCs. AJR 1997; 169:355–367
 Park CM, Goo JM, Lee HJ, et al. CT findings of 6. 
atypical adenomatous hyperplasia in the lung. Ko-
rean J Radiol 2006; 7:80–86
 Henschke CI, Yankelevitz DF, Mirtcheva R. CT 7. 
screening for lung cancer: frequency and signifi-
cance of part-solid and nonsolid nodules. AJR 
2002; 178:1053–1057
 Li F, Sone S, Abe H, MacMahon H, Doi K. Malig-8. 
nant versus benign nodules at CT screening for 
lung cancer: comparison of thin-section CT find-
ings. Radiology 2004; 233:793–798
Nakata M, Saeki H, Takata I, et al. Focal ground-9. 
glass opacity detected by low-dose helical CT. 
Chest 2002; 121:1464–1467
vanSonnenberg E, Lin AS, Deutsch AL, Mattrey 10. 
RF. Percutaneous biopsy of difficult mediastinal, 
hilar, and pulmonary lesions by computed-tomo-
graphic guidance and a modified coaxial tech-
nique. Radiology 1983; 148:300–302
Khouri NF, Stitik FP, Erozan YS, et al. Transtho-11. 
racic needle aspiration biopsy of benign and ma-
lignant lung lesions. AJR 1985; 144:281–288
Stanley JH. Lung lesions: cytologic diagnosis by 12. 
fine-needle biopsy. Radiology 1987; 162:389–391
Westcott JL. Percutaneous transthoracic needle 13. 
biopsy. Radiology 1988; 169:593–601
Yankelevitz DF, Henschke CI, Koizumi JH, Al-14. 
torki NK, Libby D. CT-guided transthoracic nee-
dle biopsy of small solitary pulmonary nodules. 
Clin Imaging 1997; 21:107–110
Larscheid RC. Percutaneous transthoracic needle 15. 
aspiration biopsy: a comprehensive review of its 
current role in the diagnosis and treatment of lung 
tumors. Chest 1998; 114:704–709
Tsukada H, Satou T, Iwashima A, Souma T. Diag-16. 
nostic accuracy of CT-guided automated needle 
biopsy of lung nodules. AJR 2000; 175:239–243
Austin JH, Muller NL, Friedman PJ, et al. Glos-17. 
sary of terms for CT of the lungs: recommenda-
tions of the Nomenclature Committee of the 
Fleischner Society. Radiology 1996; 200:327–331
Travis WD, Brambilla E, Muller-Hermelink HK, 18. 
Harris CC. World Health Organization classifica-
tion of tumours: pathology and genetics of 
tumours of the lung, pleura, thymus and heart. 
Lyon, France: International Agency for Research 
on Cancer Press, 2004
Kaneko M, Kusumoto M, Kobayashi T, et al. 19. 
Computed tomography screening for lung carci-
noma in Japan. Cancer 2000; 89:2485–2488
MacMahon H, Austin JHM, Gamsu G, et al. 20. 
Guidelines for management of small pulmonary 
nodules detected on CT scans: a statement from 
the Fleischner Society. Radiology 2005; 
237:395–400
Travis WD, Garg K, Franklin WA, et al. Evolving 21. 
concepts in the pathology and computed tomogra-
phy imaging of lung adenocarcinoma and bron-
chioloalveolar carcinoma. J Clin Oncol 2005; 
23:3279–3287
Suzuki K, Yokose T, Yoshida J, et al. Prognostic 22. 
significance of the size of central fibrosis in pe-
ripheral adenocarcinoma of the lung. Ann Thorac 
Surg 2000; 69:893–897
Oh J-Y, Kwon S-Y, Yoon H-I, et al. Clinical sig-23. 
nificance of a solitary ground-glass opacity (GGO) 
lesion of the lung detected by chest CT. Lung Can-
cer 2007; 55:67–73
Nakamura H, Saji H, Ogata A, Saijo T, Okada S, 24. 
Kato H. Lung cancer patients showing pure 
ground-glass opacity on computed tomography 
are good candidates for wedge resection. Lung 
Cancer 2004; 44:61–68
Shimizu K, Ikeda N, Tsuboi M, Hirano T, Kato H. 25. 
Percutaneous CT-guided fine needle aspiration for 
lung cancer smaller than 2 cm and revealed by 
ground-glass opacity at CT. Lung Cancer 2006; 
51:173–179
Westcott JL, Rao N, Colley DP. Transthoracic 26. 
needle biopsy of small pulmonary nodules. Radi-
ology 1997; 202:97–103
Wang SE, Nieberg RK. Fine needle aspiration cy-27. 
tology of sclerosing hemangioma of the lung, a 
mimicker of bronchioloalveolar carcinoma. Acta 
Cytol 1986; 30:51–54
Greif J, Marmur S, Schwarz Y, Man A, Starosel-28. 
sky AN. Percutaneous core cutting needle biopsy 
compared with fine-needle aspiration in the diag-
nosis of peripheral lung malignant lesions: results 
in 156 patients. Cancer 1998; 84:144–147
Klein JS, Salomon G, Stewart EA. Transthoracic 29. 
needle biopsy with a coaxially placed 20-gauge 
automated cutting needle: results in 122 patients. 
Radiology 1996; 198:715–720
Li H, Boiselle PM, Shepard JO, Trotman-Dicken-30. 
son B, McLoud TC. Diagnostic accuracy and 
safety of CT-guided percutaneous needle aspira-
tion biopsy of the lung: comparison of small and 
large pulmonary nodules. AJR 1996; 167:105–109
Laurent F, Latrabe V, Vergier B, Montaudon M, 31. 
Vernejoux JM, Dubrez J. CT-guided transthoracic 
needle biopsy of pulmonary nodules smaller than 
20 mm: results with an automated 20-gauge coaxi-
al cutting needle. Clin Radiol 2000; 55:281–287
Wallace MJ, Krishnamurthy S, Broemeling LD, et 32. 
al. CT-guided percutaneous fine-needle aspiration 
biopsy of small (< or = 1-cm) pulmonary lesions. 
Radiology 2002; 225:823–828
Ohno Y, Hatabu H, Takenaka D, et al. CT-guided 33. 
transthoracic needle aspiration biopsy of small 
(≤ 20 mm) solitary pulmonary nodules. AJR 2003; 
180:1665–1669
Montaudon M, Latrabe V, Pariente A, Corneloup 34. 
O, Begueret H, Laurent F. Factors influencing ac-
curacy of CT-guided percutaneous biopsies of pul-
monary lesions. Eur Radiol 2004; 14:1234–1240
Lucidarme O. Intrapulmonary lesions: percutaneous 35. 
automated biopsy with a detachable, 18-gauge, coax-
ial cutting needle. Radiology 1998; 207:759–765
Goralnik CH, O’Connell DM, el Yousef SJ, Haaga 36. 
JR. CT-guided cutting-needle biopsies of selected 
chest lesions. AJR 1988; 151:903–907
Staroselsky AN. Additional information from per-37. 
cutaneous cutting needle biopsy following fine-
needle aspiration in the diagnosis of chest lesions. 
Chest 1998; 113:1522–1525
Arakawa H, Nakajima Y, Kurihara Y, Niimi H, 38. 
Ishikawa T. CT-guided transthoracic needle biopsy: a 
comparison between automated biopsy gun and fine 
needle aspiration. Clin Radiol 1996; 51:503–506
Pappa VI, Hussain HK, Reznek RH, et al. Role of 39. 
image-guided core-needle biopsy in the manage-
ment of patients with lymphoma. J Clin Oncol 
1996; 14:2427–2430
Travis WD, Garg K, Franklin WA, et al. Bronchi-40. 
oloalveolar carcinoma and lung adenocarcinoma: 
the clinical importance and research relevance of 
the 2004 World Health Organization pathologic 
criteria. J Thorac Oncol 2006; 1:S13–S19
vanSonnenberg E, Casola G, Ho M, et al. Difficult 41. 
thoracic lesions: CT-guided biopsy experience in 
150 cases. Radiology 1988; 167:457–461
Kazerooni EA, Lim FT, Mikhail A, Martinez FJ. 42. 
Risk of pneumothorax in CT-guided transthoracic 
needle aspiration biopsy of the lung. Radiology 
1996; 198:371–375
Winer-Muram HT. The solitary pulmonary nod-43. 
ule. Radiology 2006; 239:34–49
Murphy JM, Gleeson FV, Flower CD. Percutaneous 44. 
needle biopsy of the lung and its impact on patient 
management. World J Surg 2001; 25:373–379
Cummings SR, Lillington GA, Richard RJ. Man-45. 
aging solitary pulmonary nodules: the choice of 
strategy is a “close call.” Am Rev Respir Dis 1986; 
134:453–460
Ost D, Fein A. Evaluation and management of the 46. 
solitary pulmonary nodule. Am J Respir Crit Care 
Med 2000; 162:782–787
Hasegawa M, Sone S, Takashima S, et al. Growth 47. 
rate of small lung cancers detected on mass CT 
screening. Br J Radiol 2000; 73:1252–1259
Aoki T, Nakata H, Watanabe H, et al. Evolution of 48. 
peripheral lung adenocarcinomas: CT findings 
correlated with histology and tumor doubling 
time. AJR 2000; 174:763–768
Cummings SR, Lillington GA, Richard RJ. Esti-49. 
mating the probability of malignancy in solitary 
pulmonary nodules: a Bayesian approach. Am Rev 
Respir Dis 1986; 134:449–452
